Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights

Iain Macdougall; Simon D. Roger; Angel de Francisco; David Goldsmith; Huub Schellekens; Hans Ebbers; Wolfgang Jelkmann; Gerard London; Nicole Casadevall; Walter H. Hoerl; David M. Kemeny; Carol Pollock

doi:10.1038/ki.2011.500

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights

Iain Macdougall, Simon D. Roger, Angel de Francisco, David Goldsmith, Huub Schellekens, Hans Ebbers, Wolfgang Jelkmann, Gerard London, Nicole Casadevall, Walter H. Hoerl, David M. Kemeny, Carol Pollock

Research output: Contribution to journal › Literature review › peer-review

97 Citations (Scopus)

Abstract

Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.

Original language	English
Pages (from-to)	727-732
Number of pages	6
Journal	Kidney International
Volume	81
Issue number	8
DOIs	https://doi.org/10.1038/ki.2011.500
Publication status	Published - Apr 2012

Keywords

anemia
chronic kidney disease
clinical nephrology
pure red cell aplasia
RECOMBINANT-HUMAN-ERYTHROPOIETIN
ANTIERYTHROPOIETIN ANTIBODIES
NEUTRALIZING ANTIBODIES
INTERFERON-BETA
EPOETIN-ALPHA
IMMUNOGENICITY
BIOPHARMACEUTICALS
ASSOCIATION
PROTEINS
EFFICACY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/ki.2011.500

Cite this

Macdougall, I., Roger, S. D., de Francisco, A., Goldsmith, D., Schellekens, H., Ebbers, H., Jelkmann, W., London, G., Casadevall, N., Hoerl, W. H., Kemeny, D. M., & Pollock, C. (2012). Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney International, 81(8), 727-732. https://doi.org/10.1038/ki.2011.500

@article{f5f283c9ec464967b682758c562db9e0,

title = "Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights",

abstract = "Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.",

keywords = "anemia, chronic kidney disease, clinical nephrology, pure red cell aplasia, RECOMBINANT-HUMAN-ERYTHROPOIETIN, ANTIERYTHROPOIETIN ANTIBODIES, NEUTRALIZING ANTIBODIES, INTERFERON-BETA, EPOETIN-ALPHA, IMMUNOGENICITY, BIOPHARMACEUTICALS, ASSOCIATION, PROTEINS, EFFICACY",

author = "Iain Macdougall and Roger, {Simon D.} and {de Francisco}, Angel and David Goldsmith and Huub Schellekens and Hans Ebbers and Wolfgang Jelkmann and Gerard London and Nicole Casadevall and Hoerl, {Walter H.} and Kemeny, {David M.} and Carol Pollock",

year = "2012",

month = apr,

doi = "10.1038/ki.2011.500",

language = "English",

volume = "81",

pages = "727--732",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "8",

}

Macdougall, I, Roger, SD, de Francisco, A, Goldsmith, D, Schellekens, H, Ebbers, H, Jelkmann, W, London, G, Casadevall, N, Hoerl, WH, Kemeny, DM & Pollock, C 2012, 'Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights', Kidney International, vol. 81, no. 8, pp. 727-732. https://doi.org/10.1038/ki.2011.500

TY - JOUR

T1 - Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents

T2 - new insights

AU - Macdougall, Iain

AU - Roger, Simon D.

AU - de Francisco, Angel

AU - Goldsmith, David

AU - Schellekens, Huub

AU - Ebbers, Hans

AU - Jelkmann, Wolfgang

AU - London, Gerard

AU - Casadevall, Nicole

AU - Hoerl, Walter H.

AU - Kemeny, David M.

AU - Pollock, Carol

PY - 2012/4

Y1 - 2012/4

N2 - Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.

AB - Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.

KW - anemia

KW - chronic kidney disease

KW - clinical nephrology

KW - pure red cell aplasia

KW - RECOMBINANT-HUMAN-ERYTHROPOIETIN

KW - ANTIERYTHROPOIETIN ANTIBODIES

KW - NEUTRALIZING ANTIBODIES

KW - INTERFERON-BETA

KW - EPOETIN-ALPHA

KW - IMMUNOGENICITY

KW - BIOPHARMACEUTICALS

KW - ASSOCIATION

KW - PROTEINS

KW - EFFICACY

U2 - 10.1038/ki.2011.500

DO - 10.1038/ki.2011.500

M3 - Literature review

SN - 0085-2538

VL - 81

SP - 727

EP - 732

JO - Kidney International

JF - Kidney International

IS - 8

ER -

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this